Cannabidiol Capsules

DRUG4 trials

Sponsors

Zentralinstitut Fuer Seelische Gesundheit, University of Northern Colorado, Central Institute of Mental Health, Mannheim

Conditions

Alcohol AddictionAlcohol dependenceAlcoholismHealthyRemitted early phase schizophrenia

Phase 2

CBD-ESPRIT - Enhancing recovery in early schizophrenia – a multi-center, two-arm, double-blind, randomized clinical trial investigating cannabidiol vs. placebo as an add-on to an individualized antipsychotic treatment

SuspendedCTIS2024-517198-26-00

Zentralinstitut Fuer Seelische GesundheitRemitted early phase schizophrenia

Start: 2017-02-17Target: 180Updated: 2024-11-13

A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence

RecruitingNCT06845124

Central Institute of Mental Health, MannheimAlcohol Addiction, Alcoholism

Start: 2025-07-22End: 2028-09-30Target: 150Updated: 2026-02-03

ICONICplus - Randomized, double-blind, placebo-controlled trial to investigate the Effects of Cannabidiol plus Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence

RecruitingCTIS2024-518164-12-00

Zentralinstitut Fuer Seelische GesundheitAlcohol dependence

Start: 2025-06-16Target: 150Updated: 2025-05-16

Unknown Phase

Effects of CBD on 2 Mile Run Time Trial Performance

Active, not recruitingNCT06364254

University of Northern ColoradoHealthy

Start: 2023-11-11End: 2024-05-30Target: 30Updated: 2024-06-03

Related Papers

Investigation of the combined effects of cannabidiol plus naltrexone on alcohol craving in alcohol dependence: study protocol of a phase II randomised, double-blind, placebo-controlled, parallel-group trial – ICONICplus Trial

BMJ Open2025-08-01